Tamoxifen prevents sulpiride-induced weight gain in female rats

Pharmacology, Biochemistry, and Behavior
T BaptistaS Weiss

Abstract

To evaluate its potential utility in counteracting neuroleptic-induced obesity, the effects of long-term administration of tamoxifen (TAM) on body weight (BW) and food intake (FI) of gonadally intact and sulpiride-treated (SUL) female rats were assessed. In addition, estradiol and prolactin serum levels were measured in rats treated with SUL. SUL plus TAM and SUL plus bromocriptine (BR). TAM, at doses of 10, 50 and 100 micrograms, significantly decreased BW gain: FI was significantly reduced at the doses of 50 and 100 micrograms. In addition, doses of TAM ranging from 5-100 micrograms completely prevented SUL-induced BW gain and hyperphagia. BR also prevented SUL effects on BW and FI. In contrast to BR, concomitant administration of TAM did not prevent SUL-induced hyperprolactinemia. Estradiol levels were not modified by SUL alone or SUL plus BR, but they were significantly increased in the animals treated with TAM plus SUL. Neuroleptic-induced obesity in female rats might be related to an alteration in gonadal steroid balance secondary to hyperprolactinemia. While BR might counteract neuroleptic-induced weight gain by preventing hyperprolactinemia, TAM might directly interact with estrogen receptors, or indirectly increase est...Continue Reading

References

Jan 11, 1979·Nature·J W Kebabian, D B Calne
Mar 1, 1979·Physiology & Behavior·G N Wade, J M Gray
Aug 1, 1979·Pharmacology, Biochemistry, and Behavior·C J Earley, B E Leonard
Feb 1, 1976·Journal of Comparative and Physiological Psychology·E J Roy, G N Uade
Jan 1, 1992·Neuroscience and Biobehavioral Reviews·G N Wade, J E Schneider
Jan 1, 1991·Acta Obstetricia Et Gynecologica Scandinavica·A DorevitchM Stark
Nov 1, 1990·Endocrine Reviews·V C Jordan, C S Murphy
May 1, 1989·Pharmacology, Biochemistry, and Behavior·M A ParadaM de Quijada
Sep 1, 1986·The American Journal of Psychiatry·Z NestelbaumG T Reardon
Apr 1, 1987·Journal of Clinical Psychopharmacology·N CorreaB Birmaher
Oct 5, 1988·Neuroscience Letters·T BaptistaE Murzi
Oct 1, 1986·Brain Research Bulletin·B J MooreJ S Stern
Sep 1, 1985·Acta Psychiatrica Scandinavica·A K Gopalaswamy, R Morgan
Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·T Di Paolo, P Falardeau
May 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·P J BeumontD H Wiles
May 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·P J BeumontD H Wiles
Feb 1, 1981·Drugs·G M SimpsonJ J Sramek
Apr 1, 1983·British Journal of Pharmacology·S P BowmanI D Morris
Sep 1, 1983·Biology of Reproduction·C H Tsai-MorrisA M Brodie
Nov 1, 1980·Molecular and Cellular Endocrinology·C WangG F Erickson
Jun 1, 1981·Journal of Comparative and Physiological Psychology·R J WaldbilligB G Stanley
Mar 1, 1995·Pharmacopsychiatry·T BaptistaL Hernàndez
Feb 19, 1994·Lancet·F E van LeeuwenF W Diepenhorst
Jan 1, 1994·Psychoneuroendocrinology·R D Oades, R Schepker
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T FornanderB von Schoultz
Jul 1, 1993·Proceedings of the Society for Experimental Biology and Medicine·W S BranhamD M Sheehan
May 1, 1993·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández
May 1, 1993·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández

❮ Previous
Next ❯

Citations

Jul 11, 2002·European Journal of Pharmacology·Trino BaptistaSerge Beaulieu
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Nov 1, 2003·Pharmacology, Biochemistry, and Behavior·Abegale W HartfieldPeter G Clifton
Mar 18, 1999·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández
Jun 16, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·T BaptistaL Hernández
Feb 5, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·T BaptistaL Hernández
Aug 12, 1999·Acta Psychiatrica Scandinavica·T Baptista
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Oct 16, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jing ZuoXiao-Hong Lu
Jul 20, 2002·International Clinical Psychopharmacology·U WernekeT A B Sanders
Jan 5, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·T BaptistaL Hernàndez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.